Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b
Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b
Third Affiliated Hospital, Sun Yat-Sen University
100 participants
Jan 1, 2014
OBSERVATIONAL
Conditions
Summary
The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.
Eligibility
Inclusion Criteria3
- Patients received anti-HBV therapy with nucleos(t)ide analogs.
- Last anti-HBV therapy should continue for at least 2 years.
- For HBeAg positive patients, HBV DNA should keep negative for at least 1 year after HBeAg seroconversion before the therapy ending; for HBeAg negative patients, HBV DNA should keep negative for at least 2 years before the therapy ending.
Exclusion Criteria5
- Liver cirrhosis, HCC;
- Patients with other factors causing active liver diseases;
- Pregnancy or lactation;
- Patients with HIV infection or congenital immune deficiency diseases;
- Patients with severe diabetes, autoimmune diseases, other important organ dysfunctions and other serious complications.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02883647